€30.00
0.00% yesterday
Xetra, May 14, 05:36 pm CET
ISIN
DE0005227235
Symbol
BIO3
Index
Sector

BIOTEST AG Stock price

€30.00
+0.00 0.00% 1M
+3.50 13.21% 6M
+3.00 11.11% YTD
+2.40 8.70% 1Y
-6.30 17.36% 3Y
+9.50 46.34% 5Y
-44.50 59.73% 10Y
Xetra, Closing price Wed, May 14 2025
+0.00 0.00%
ISIN
DE0005227235
Symbol
BIO3
Index
Sector

Key metrics

Market capitalization €1.19b
Enterprise Value €1.74b
P/E (TTM) P/E ratio 44.97
EV/Sales (TTM) EV/Sales 2.40
P/S ratio (TTM) P/S ratio 1.63
P/B ratio (TTM) P/B ratio 2.24
Dividend yield 0.13%
Last dividend (FY24) €0.04
Revenue growth (TTM) Revenue growth 6.09%
Revenue (TTM) Revenue €726.20m
EBIT (operating result TTM) EBIT €78.80m
Cash position €119.30m
EPS (TTM) EPS €0.67
Show more

Is BIOTEST AG a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,785 stocks worldwide.

BIOTEST AG Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast BIOTEST AG:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast BIOTEST AG:

Hold
100%

Financial data from BIOTEST AG

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
726 726
6% 6%
100%
- Direct Costs 502 502
24% 24%
69%
224 224
20% 20%
31%
- Selling and Administrative Expenses 88 88
9% 9%
12%
- Research and Development Expense 57 57
15% 15%
8%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 79 79
40% 40%
11%
Net Profit 26 26
79% 79%
4%

In millions EUR.

Don't miss a Thing! We will send you all news about BIOTEST AG directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BIOTEST AG Stock News

AD HOC NEWS
3 days ago
Biotest AG / DE0005227235
AD HOC NEWS
3 days ago
Biotest AG / DE0005227235
AD HOC NEWS
about 2 months ago
Biotest AG / DE0005227235
More BIOTEST AG News

Company Profile

Biotest AG engages in the development, manufacture, and marketing of plasma proteins and biotherapeutic drugs. It operates through the following segments: Therapy, Plasma and Services, and Other. The Therapy segment develops and produces blood plasma-based immunoglobulins, clotting factors, and albumins which are used to treat diseases of the immune system, haematological diseases, and in intensive care medicine. The Plasma and Services segment includes the areas of plasma sales and contract manufacturing. The Other segment refers to the merchandise business. The company was founded by Carl Adolf Schleussner and Hans Schleussner in 1946 and is headquartered in Dreieich, Germany.

Head office Germany
CEO Peter Janssen
Employees 2,495
Founded 1946
Website www.biotest.de

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today